pumper_stumper
1 week ago
You almost have to wonder, is he smart enough to have planned this so that he could get a 6-9 month free pass for having zero progress? Of course, if this were a real company, an audit wouldn't stand in the way of drug development. But this is a one thread company, anything can be used as an excuse to hold up all progress on everything.
So was it planned, or is he THAT incompetent? One of those has to be true. That's part of what makes pinks so fun to watch!
pumper_stumper
1 week ago
Summary of today's conference call!
BIG ONE! The SEC shut down RGBP's new offering due to an existing offering from "5,6, 8 years ago" (his exact words) still being open! (aren't you impressed with how much he knows about his own company? 5,6 or 8?)
You want to talk about CEO incompetence? This is an all time great! Not even being aware that his prior offering from YEARS ago was still open! It's a one person company, he has no one else to blame!
So, NOW, they have to do a 180, rescind the Form 15 filing that made them not SEC compliant, and NOW they have to get audited first, and close the old offering, then restart the new offering before any financing can begin! Just realize that he did already try to get reaudited, for MONTHS, but then stopped in the middle of it, last year. Of course, common sense would tell you the audit was stopped because the audit found issues!
Well now the SEC is forcing him to restart the audit before any offering can be done!
What does this mean? MANY MANY months of blaming the auditors for delays, and throwing up his hands when asked for status and end date. "that's up to the auditors and I'm having a hard time getting a date from them"
He was asked how much was raised before the SEC stopped them. His reply? "A bunch of money". How's that for transparency? The funds had to be returned.
So, more evidence of incompetence and doing anything but being very transparent!
Now he gets months more of doing nothing, and gets to blame the delay to riches on someone else! This is a scammer CEO's dream situation!!!!
pumper_stumper
1 week ago
Well we get a 30 minute song and dance show today from Koos (video conference call). What can we expect? Avoidance of discussing actual funding received, more meaningless talk about "setting parameters and milestones of the early parts of the test" (same thing said in prior one), and lots of "we're excited"! Then we'll get to hear Mr Science ramble of about how some drugs theoretically act biologically, but ZERO on any recent actual published testing results, because there are none. Will be interesting to see how he fills up a half hour, since NOTHING will be done in testing unless they get funding.
pumper_stumper
2 weeks ago
Thanks, since he went to an uncredited online "University" (the pink sheet equivalent of education), likely they don't participate in posting such great works as Mr Koos online. It likely would be an embarrassment anyway. I searched for both thesis and dissertation.
PhD theses are generally publicly available and searchable—especially in the U.S., U.K., Canada, and many other countries with open academic publishing norms. Here’s how it typically works:
🔍 Where PhD theses are usually found:
University Repositories
Most universities require PhD candidates to deposit their dissertation in a digital repository (e.g., Harvard DASH, MIT DSpace, etc.), which are indexed and searchable online.
ProQuest Dissertations & Theses
In the U.S., ProQuest is a massive database of theses and dissertations. Many American universities submit all PhD theses here. Access may require a subscription, but basic search is open.
Google Scholar / WorldCat / Open Access Repositories
Some theses also appear here, especially if the author has uploaded them to academic sharing platforms like Academia.edu or ResearchGate.
I was unable to locate a publicly available PhD thesis titled "Examining the Efficacy of Telemarketing Fundraisers as a Venture Capital Alternative in the Biotechnology Industry: A Case Study of Cell Bio-Systems, Inc" authored by David Koos in major academic databases or repositories. This specific work does not appear in platforms such as arXiv or Taylor & Francis, and there are no publicly available records indicating its publication.
?I was unable to locate a published paper titled "Examining the Efficacy of Telemarketing Fundraisers as a Venture Capital Alternative in the Biotechnology Industry: A Case Study of Cell Bio-Systems, Inc" authored by David Koos in major academic databases or repositories.
If this thesis exists, it might be an internal report, a conference presentation, or a document with limited distribution. To pursue further information, you might consider:
Contacting Cell Bio-Systems, Inc.: They may have archives or records of internal studies or reports.?
Reaching out to David Koos directly: If he is affiliated with an institution or organization, they might provide contact information or access to his publications.?
Exploring business registries or press releases: Sometimes, companies release summaries or findings of studies in press releases or business filings.
Musical Shares
2 weeks ago
I learned a long time ago that being a pessimistic person is way better on the mind, body and soul. My philosophy is, if you are already negative about everything then it can't get worse. If it becomes positive, then you just won.
Stupid simple. 🤣
There are three (3) principles I live by:
1. I watch lazy people to find the easiest and most efficient way to do things.
2. I listen to negative people before starting something to find out all the ways it could go badly.
3. And I learn from stupid people who teach me what not to do.
Yes, anyone that took a look a a 5 year history here (something that no shareholder here has ever done), you can see he just jumps from working on drug to drug, each time it is because the other one suddenly has a better business case.
This is the same thing as the "biotech" trick called "screening platform acquisition" in the OTC. A ticker will "acquire" a "screening platform," call themselves a "biotech" company and never actually produce anything other than "data" and then write about it. The idea is a biotech never needs to make revenues and only has to produce fluff PR's to keep shareholders motivated.
It's the same thing Koos is doing with bouncing back and fourth here. It's simple, effective and keeps the "company" alive.
The video conference calls are always hilarious. 10 minutes of him sitting in a chair in a room painted with white walls only where he keeps saying the same things as last year. 🤣
It still cracks me up that he writes in his annual reports that he rents a space from his own "realty company" and calls it his home/office/lab. I get the home/office but scientific research lab? 🤣
What are you working with a 1956 science kit?
pumper_stumper
2 weeks ago
You are one of the rare ones that see this for what it is and yes, the comedy factor is reason alone to follow.
Koos called off the last paid video conference call, which was scheduled to be only 10 minutes long, hours before it was to start, due to "bronchitis", which had me in stitches. The idea a CEO couldn't make it through a 10 minute call for that is just ridiculous.
Yes, anyone that took a look a a 5 year history here (something that no shareholder here has ever done), you can see he just jumps from working on drug to drug, each time it is because the other one suddenly has a better business case. I haven't posted all my recent findings, but he did try to run HemaXellerate through some central american testing, about 9 years ago, and like usual, for a while posted all the "great progress" (with zero data or proof) until either the results showed it was going nowhere, or he ran out of $. Now, years later, he's back with it, and if he gets some funding, best case, will run the same preliminary lab set up and simple early tests as he did 9 years ago, and pocket the rest of the offering $.
Just like you, I have a history of pink sheet CEOs changing their approach due to my posts. Good old Roxanna Weber of Emax used to say "soon" all the time, in answer to when things would be completed, a totally meaningless word. Well for months me and a few others would just post silly things about the answer being "soon", and ridiculing her. It became a running joke. Well after months of this, she instead started saying "in the very near term", which was a great compliment to me, and just as funny and pointless.
Musical Shares
2 weeks ago
Thanks for the explanation.
My favorite part was:
Midstream in the "great progress" testing one of his drugs, he stopped dead on that testing, and went back to HemaXellerate, which had an IND like a decade ago, and he claims he is going to raise money to do a phase 1 test on it. The best part is that he did this ONLY after I submitted a question on his call, months ago, to embarrass him as to why he did nothing with this drug, 10 years after getting an IND! The next month he announced the shift back to HemaXellerate! (ping pong) So basically I am calling the shots here!
Nice work!
I had something similar on another ticker where I wrote these posts and the next day the "CEO" would magically write a "PR" on the exact things I pointed out! He even went as far as to copy and paste one post telling him how to run his business!
Comedy gold. Needless to say he gave up when I just kept pointing things out and "sold" the ticker. 🤣
This guy is definitely playing ping pong. In what world does someone create an IND, abandon it and then state he is bringing it back? If something was actually good then many "big pharma's" and even medium size would be interested in helping to fund it.
It seems he is still doing this "I'm working on funding" bit.
This is like real life Seinfeld. Only better.
pumper_stumper
2 weeks ago
Yes, I figured I would see if I could lure you back here! I miss seeing your posts here, and yes, I'm back.
Although post wise, seems like the cheerleaders for this scam are either in hiding or licking their wounds, the Koos scam still continues!
Well you might have missed that months after the reverse he paid a "dividend" which in effect undid part of the reverse. These additional shares were like throwing gasoline on a fire, and sent it lower. He knew that pink sheet investors see the word "dividend" and jump to the conclusion this means the company is growing. Instead, they got Koos'ed again!
Midstream in the "great progress" testing one of his drugs, he stopped dead on that testing, and went back to HemaXellerate, which had an IND like a decade ago, and he claims he is going to raise money to do a phase 1 test on it. The best part is that he did this ONLY after I submitted a question on his call, months ago, to embarrass him as to why he did nothing with this drug, 10 years after getting an IND! The next month he announced the shift back to HemaXellerate! (ping pong) So basically I am calling the shots here!
There is another video call next week where he will dance around this again, wanting to give people the impression his is making progress raising more money, yet still will not be going forward with any testing. Just lots of talk of "being excited". The over under on that phrase is about 5 per call!
pumper_stumper
4 weeks ago
Who said: " The market teaches expensive lessons, and has no sympathy. For those who continue to ignore facts, there are more declines coming, I PROMISE!"
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169149951
Since I was hear last, RGBP has (Split adjusted) fallen from $2.92, to $0.05 So down only 98% In just 15 months! And this after 90% declines from prior years! Sick! And Fun!
Nothing has changed except SOME of the long time shareholders with 99+% losses are starting to see the light! Is that all it takes to figure it out!
Once again, the market teaches expensive lessons. If you continue to invests in scams, the market will teach you expensive lessons! It still holds!
It's so joyful to see when markets work!
pumper_stumper
4 weeks ago
It was filed because Koos's auditor was a slimeball (similar types attract each other), and was banned from auditing by the SEC. The SEC notes show that basically this auditor would hardly look into things. In other words the perfect auditor for a pink sheet scam! The SEC required all companies that this auditor audited, to hire a REAL auditor and get re-audited. You know Koos won't stand and pay for a real audit!
As such they are no longer an audited company. Koos initially did try to hire a new auditor, but this new one was legitimate, so no way RGBP was going to pass without a lot of work/rework. So Koos stopped the audit and it's no longer even being pursued! (this is the pinks, who cares about being audited... he knows his audience! )
This means that they can no longer be an SEC reporting company, so he had no choice but to file a SEC 15 to cut ties with the SEC and get back to what all "quality" companies do, being alternative reporting via OTC Markets.
bigtalan
4 months ago
It took awhile , but it is where it was almost when the R/S took place . Koos and his scams
This phrase refers to a legal document, specifically "Form 15" filed with the Securities and Exchange Commission (SEC), which essentially signifies a company's certification that it is terminating its registration of a class of securities under Section 12(g) of the Securities Exchange Act of 1934, meaning they no longer need to file periodic reports because they have become a private company, or that they are suspending their duty to file reports under Sections 13 and 15(d) of the same act; effectively removing their public reporting obligations.
Key points about this phrase:
Form 15: This is the official SEC form used to make this notification.
Section 12(g): This section of the Securities Exchange Act outlines the requirements for a company to register its securities with the SEC and become subject to periodic reporting.
Sections 13 and 15(d): These sections dictate the specific reporting requirements that a public company must follow.
When a company might file this form:
When the number of shareholders of a publicly traded class of securities falls below a certain threshold, allowing them to "go private".
If a company is undergoing a merger or acquisition that results in a significant reduction in public shareholders.
Bigfootbud
5 months ago
Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate
SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC Pink: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate™, the company’s innovative stem cell-derived therapy, which has already received FDA clearance. While the initial focus is on treating aplastic anemia, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in a market poised for significant growth.
HemaXellerate™ is designed to stimulate bone marrow regeneration following injury caused by autoimmune conditions, chemotherapy, or radiation. While the company’s initial target is aplastic anemia—a rare orphan indication—it sees substantial potential in treating chemotherapy-induced bone marrow suppression, a market valued at over $1 billion annually. This is evidenced by the success of products like Neulasta, which addresses similar unmet needs.
“Aplastic anemia patients without access to bone marrow transplantation face limited options,” said Dr. David Koos, Chairman and CEO of Regen BioPharma. “With FDA clearance to begin clinical trials, HemaXellerate™ has the potential to redefine the treatment landscape—not just for aplastic anemia but for a wide range of hematological disorders. This is a pivotal moment for our company as we work to deliver life-changing therapies to patients worldwide.”
To ensure the trial’s success, Regen BioPharma has partnered with a clinical research organization (CRO) known for its expertise in conducting complex trials. Once initiated, the study is expected to reach completion within 12 to 14 months.
Key Highlights for Investors:
Opportunity: Aplastic anemia is a rare disease with high unmet medical need, offering the potential for accelerated regulatory pathways and market exclusivity.
Massive Market Potential: Expansion into chemotherapy-induced bone marrow suppression could unlock a multi-billion-dollar market.
Strategic Execution: Collaboration with a leading CRO ensures focused execution and timeline adherence.
About Regen BioPharma, Inc.
Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
https://finance.yahoo.com/news/regen-biopharma-inc-expands-vision-210500940.html